EPS HEALTH TECH (03860) terminates acquisition of 16.23% of China Genetics' issued shares.
EPS Innovation Technology (03860) announced that they plan to acquire 16.23% of the issued shares of China Gene for 43 million Hong Kong dollars. The parties to the agreement have agreed to jointly terminate the acquisition on May 15, 2026, and neither party will bear any responsibility or further obligations. The board believes that the termination of the agreement will not have a significant adverse impact on the business and operations of the group.
EPS HEALTH TECH (03860) announced that the company intends to acquire 16.23% of the issued shares of China Gene for a total of HK$43 million. The parties to the agreement have agreed to mutually terminate the acquisition on May 15, 2026, without any party bearing responsibility or further obligations. The Board believes that the termination of the agreement will not have a significant adverse impact on the business and operations of the Group.
Related Articles
Bank of China (03988): The issuance of non-fixed-term capital bonds with markdown has been completed.
PHOENIX TV (2008) subsidiary plans to produce a series of documentary programs with traditional Chinese medicine culture as the theme, and has signed a third cooperation agreement with Bauhinia Culture Hong Kong.
HAOHAI BIOTEC (06826) spent HK$788,000 on May 15 to repurchase 36,000 shares.
Bank of China (03988): The issuance of non-fixed-term capital bonds with markdown has been completed.
PHOENIX TV (2008) subsidiary plans to produce a series of documentary programs with traditional Chinese medicine culture as the theme, and has signed a third cooperation agreement with Bauhinia Culture Hong Kong.
HAOHAI BIOTEC (06826) spent HK$788,000 on May 15 to repurchase 36,000 shares.
